Stay updated on Trametinib and Docetaxel for KRAS+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trametinib and Docetaxel for KRAS+ NSCLC Clinical Trial page.

Latest updates to the Trametinib and Docetaxel for KRAS+ NSCLC Clinical Trial page
- Check2 days agoChange DetectedA new version entry (443) was added on 2026-06-12 introducing the Study Status and Contacts/Locations sections to the record history, and the last update date was set to 2026-06-15; a 2026-05-29 entry was removed.SummaryDifference0.1%

- Check9 days agoChange DetectedThe record history now shows that recruitment has ceased, indicating the study is no longer enrolling participants. The history also reflects a new revision (v3.6.0) and the removal of the prior revision (v3.5.5), indicating updates to the study documentation.SummaryDifference0.0%

- Check16 days agoChange DetectedRevision label updated from v3.5.4 to v3.5.5 on the page. This indicates a small internal update to the site's history display rather than changes to study information.SummaryDifference0.0%

- Check24 days agoChange DetectedNew history entries on 2026-05-28 and 2026-05-29 add core content for Contacts/Locations and Study Status (including an item labeled 442). The entry dated 2026-05-01 was removed from the history.SummaryDifference0.1%

- Check38 days agoChange DetectedA new page revision entry (v3.5.4) has been added, replacing the previous revision (v3.5.3). This reflects a software/metadata update to the page rather than content changes.SummaryDifference0.0%

- Check52 days agoChange DetectedTwo new history entries were added on 2026-04-09 and 2026-04-30 (versions 440 and 441) reflecting updates to the Study Status and Contacts/Locations sections, with a subsequent entry on 2026-05-01 referencing these changes. The 2026-03-04 entry was deleted.SummaryDifference0.1%

Stay in the know with updates to Trametinib and Docetaxel for KRAS+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trametinib and Docetaxel for KRAS+ NSCLC Clinical Trial page.